EXINI’s Artificial Intelligence enabled product received FDA clearance on GE Healthcare’s XELERIS platform

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the use of EXINI’s artificial intelligence enabled automated bone scan index (aBSI) on GE Healthcare’s Xeleris platform. EXINI has entered into a global software licensing agreement with GE Healthcare for the rights to EXINI bone, a vendor neutral stand-alone variant of aBSI that is enabled with artificial intelligence.